Infant and Child Multiple Vaccine Market Report: Trends, Forecast and Competitive Analysis to 2035

Infant and Child Multiple Vaccine Market

The future of the global infant and child multiple vaccine market looks promising with opportunities in the 12 months below and 12 months above markets. The global infant and child multiple vaccine market is expected to reach an estimated $25 billion by 2035 from $16 billion in 2027 with a CAGR of 5.5% from 2027 to 2035. The major drivers for this market are the rising vaccination awareness and the government vaccination programs.

• Lucintel forecasts that, within the type category, pentavalent vaccine is expected to witness the highest growth over the forecast period due to rising demand for simplified immunization schedules is boosting the adoption of pentavalent vaccines.
• Within the application category, 12 months above is expected to witness the higher growth due to growing emphasis on combination vaccines simplifies immunization schedules for children over 12 months, enhancing compliance and coverage.
• In terms of regions, APAC is expected to witness the highest growth over the forecast period due to the larger infant population and expanding immunization programs in Asia.

Emerging Trends in Infant and Child Multiple Vaccine Market

The multiple vaccine market for infants and children is expected to transition from episodic buying to the integration of vaccination within planning during the period 2025-2027. Governments will expand their coverage through routine immunization, and manufacturers will create combination products requiring fewer injections and less complex to administer. According to Lucintel, having an advantage will depend more on access, evidence, and reliable supply, as opposed to the volume of product.

• Combination Product Consolidation: Combination vaccines containing up to six antigens in one product continue to be recommended by the CDC in their February 2025 schedule. With this schedule, manufacturing consolidation is expected to align with the goal of fewer visits and injections to improve adherence, efficiency in procurement, and caregiver acceptance in the next three to five years.
• Thermostability: Formulations requiring thermal stability to expand the time that a vaccine can be stored from traditional refrigeration will be the focus of the 2025 immunization plan of the WHO.
• Regional Supply Diversification: The 2025-2030 strategy of Gavi places emphasis on technology transfer and regional manufacturing as well as sustainable country ownership, encouraging multiple sources of supply. This will encourage the reduction in the dependence on the overly concentrated production of supply.
• Digital Immunization Management: Calendar reminder systems and stock visibility are some of the features of electronic registries that will be available in most national programs in 2025. There are several systems that track the child to multiple scheduled doses rather than a single encounter, thereby enabling better data, evidence for tenders, and missed dose vaccinations.
• Delivery Innovation: Microarray patches and other needle-free vaccine delivery technologies continued to move through clinical trials in 2025. Development of patches designed for pediatric use also continued. Delivery technologies that do not require a dramatic shift in the cold chain are expected to change the reach of outreach programs in three to five years.

In the next five years, suppliers that offer a broad antigen coverage at the right delivery economics will dominate the vaccine market. Public sector procurement will favor sustainable options that offer strong delivery and supply, coupled with evidence of a positive impact on the program. The private market will buy convenience when safety and schedules are maintained. The market is focused on fewer visits and improved resilience with wider access within health systems.

Recent Developments in the Infant and Child Multiple Vaccine Market

The market for multiple vaccines has a projected growth period of 2025-2027. Combination schedules are increasingly prioritized by governments while manufacturers build capacity. Regulators are working on updated formulations. As demand increases for vaccines, Lucintel projects that regional procurement of multiple vaccines will focus on the economics of delivery and contribute to better public health.

• Funding Expansion: Expanding combination product procurement is a direct result of Gavi's goal to raise $9 billion by June 2025 in their 2025-2030 campaign.
• Manufacturing Localization: The Serum Institute of India's goal to produce 100 million additional pediatric vaccine doses per year will help meet demand and reduce the regional capacity dependency on concentrated hubs.
• Schedule Simplification: The WHO and UNICEF combined efforts to reduce the estimated 14.3 million zero-dose children will help driving market demand for more combination vaccines.
• Regulatory Reform: The EMA accepted changes to clinical standards for a pediatric combination vaccine and review systems, to shorten the time to market further and encourage multiple combination formulations.
• Strategic Partnerships: Sanofi has formed a partnership with a consortium to provide €500 million for pediatric combination vaccines that will cater to public health.

Over the next five years, successful suppliers will combine validated immunogenicity with reliable delivery and lower total program costs. Public tenders will compensate products that reduce the number of visits without overcomplicating cold-chain logistics. Investment in capacity will increase availability, but unpredictable policies will remain a commercial risk. Companies with pediatric evidence, flexible filling networks, and strong government relations will capture the clearest near-term opportunities.

Strategic Growth Opportunities in the Infant and Child Multiple Vaccine Market

The multiple vaccine market for infants and children is undergoing a commercial reset as immunization programs shift to fewer clinic visits, better coverage, and lower operational costs. From 2024 to 2026, advances in funding, larger birth cohort sizes, and product pipelines will drive demands. Lucintel sees five opportunities that will drive supplier positioning and procurement decisions.

• Next-generation Combination Vaccines: Products that offer protection against additional antigens and can reduce missed doses due to fewer visits will gain market share. In June 2025, Gavi's 2026-2030 strategy focused on the immunization of 500 million children. This opportunity will drive procurement as Ministries of Health favor fewer visits along with easier planning for cold chains.
• Private Pediatric Care: Market-based parents' increasing preference for convenient vaccination will provide opportunity for private hospitals and clinics to offer premium combination products. In January 2025, India's private healthcare market was estimated to be around 60% of total health spending. In the next five years, providers will create market opportunities with shorter schedules using bundled pediatric services.
• Middle-income Market Expansion: Manufacturers can create additional revenue through localized supply, partnered tenders, and age-specific formulations across Southeast Asia, Latin America, and the Middle East. In April 2025, Indonesia's national immunization program targeted over 10 million children. There will be increased demand as governments replaced fragmented purchasing with broader routine-immunization contracts.
• Thermostable Formulations: In comparison to traditional refrigerated formulations, thermostable formulations will allow vaccination outreach to extend to remote communities that lack reliable cold chains. In March 2025, WHO reported distribution losses for temperature-sensitive products in low-resource settings and stated that waste can be as high as 10% or higher in some cases.
• Digital Adherence Services: Reminder systems integrated into e-records could provide full adherence to multi-dose schedules and create a service revenue stream for manufacturers and providers. In February of 2025, UNICEF reported 14.5 million zero-dose children globally. In public and private vaccine programs, connected scheduling will differentiate within three to five years.

Service providers who can offer clinical breadth with manageable logistics will win the best tenders. There will be less market differentiation by the addition of new antigens and more differentiation through providing national vaccine schedules, financing strategies, and optimal workflows of supply and service for vaccine providers. Creating partnerships with local vaccine manufacturers will also help service providers shorten their registration timelines, and digital follow-ups will help complete vaccine services. Volume markets will reward a dependable supply of vaccines before premium pricing.

Infant and Child Multiple Vaccine Market Drivers and Challenges

The infant and child multiple vaccine market will be affected by various technological, economic, social, and regulatory factors in the coming years. Rapidly changing dynamics like the rapidly evolving technology along with growing concerns like the need for newer vaccines, combined product innovations, improved access to healthcare and prevention programs, affordability, supply, safety, and uneven distribution networks will impact the market in challenging ways, whereas factors like the trusted vaccination systems, and scaling up manufacturing and distribution capacity will create new growth opportunities. According to Lucintel, the market performance will rely largely on these new growth opportunities in the future.

The factors responsible for driving this market include :

• Increased Demand for Vaccinations: The multiple vaccine market will likely see high demand in the coming years due to an increase in the size of birth cohorts, the continuing threat of infectious diseases, and government efforts aimed at expanding coverage. Parents and health systems prefer vaccines that provide protection for multiple diseases and reduce the total number of clinic visits and the overall burden of vaccinations. In July 2025, the WHO and UNICEC reported that in 2024 89% of infants worldwide received one dose of the combined DTaP vaccine. Over the coming three to five years, demand will be sustained by the catch-up campaigns and population growth combined with resurgent infectious disease outbreaks in the developing world where substantial gaps in routine immunization still exist.
• The Growing Practice of Combination Vaccines: Innovation in the industry lean towards forming broader vaccines against diphtheria, tetanus, pertussis, polio, hepatitis B, Haemophilus influenzae type b, and other diseases. These products reduce the overall number of doses required, decrease the number of visits to clinics, and increase the convenience of administering the doses. In 2025, there were numerous national schedules using the six-in-one pediatric vaccine to counteract six different diseases. In the next three to five years, some combination vaccines will become the standard. Improving antigen and adjuvant technologies, and the therapeutic stability of vaccines will make it easier to adopt vaccines. This will only be the case until there is evidence that the vaccines stimulate the body to provide better protection. In addition, it must be clear to regulatory agencies that it will not take too long for them to assess the vaccines.
• Market Expansion Catalysts: Government and Regulatory Frameworks: Public investments, regular government purchases, and the engagement of regulatory bodies support market expansion. More governments recognize that investments in vaccines are necessary infrastructure for a healthy public. In addition, vaccines prevent hospital stays and save costs on the public purse due to long-term care. In 2025, the United States published a new scheduled immunization framework for over 15 different vaccines to be administered across the full range of the pediatric population. In the next three to five years, policy frameworks will continue to be the dominant drivers of market growth as more countries expand their immunization programs, respond to the needs for new combination vaccines, and enhance their preparedness to address outbreaks, even if regional policy dominance may vary.
• Manufacturing Efficiency: Progress toward achieving automated cell culture, fill-finish, formulation, process control, and digitalized supply chain technologies moves manufacturing toward zero waste and a greater level of output. Economies of scale can be realized by larger batch sizes due to capability platforms, resulting in decreased cost per dose and more reliable supply for high volume purchasing via state tenders. In 2025, manufacturers of vaccines continued to invest in fully automated plants capable of producing tens of millions of doses of vaccines for wider pediatric purchasing. There is a growing need for more efficient manufacturing, especially in countries that are particularly price- and time-sensitive to purchasing when demand surges and when buying during a public outbreak, coupled with an increasing demand for supply to be sustained.
• Infrastructure and Global Access: Infrastructure development that includes procurement of cold-chain machines, establishment of primary care clinics, creation of registries, and mobile vaccination services improves accessibility of pediatric vaccines. Infrastructure facilitates product delivery without loss or waste. In 2025, programs sponsored by Gavi continued efforts to provide vaccination services for over 500 million low-income country children. During the next three to five years, market access will increase with improvements in rural infrastructure and digital tracking, but access will continue to be dependent on funding, staff availability, and effective last mile distribution.

The challenges facing this market include

• Funding Pressure and Affordability: A significant amount of research, clinical tests, manufacturing capacity, and quality systems, as well as the maintenance of a cold chain, is required to make multiple vaccinations for infants and children. Public sector buyers have limitations on budgets, and their negotiations have the capability to reduce margins on supplier vaccines to a level that adversely affects the funding and investment of complex vaccine formulations. Within the next 5 years, there will most likely be delays in meeting coverage goals due to inflation, increased debt, uncertain donor funding, and a greater demand for other health care services compared to vaccinations in developing countries.
• Complexity of Supply Chain and Manufacturing: Each component of a combination vaccine necessitates multiple production steps that require extensive testing and stringent quality requirements to ensure product release. There are a number of resources that if in low supply or varying demand, such as raw materials and glass vials, can interrupt supply, even with high demand. Establishing a buffer of childhood vaccines is important because the production of vaccines is highly variable, and schedules can disrupted in as little as a few months. The next 5 years will likely maintain a high risk of concentration of suppliers and limited manufacturing that will necessitate regional production and improved forecasting to minimize supply chain gaps.
• Safety Concerns and Regulatory Barriers: Safety, stability, and the ability to schedule combination products will largely influence parental acceptance. Misinformation and vaccine hesitancy will play a significant role. Combination products must satisfy complex demand profiles across safety, immunogenicity, stability, labeling, and scheduling. Safety concerns and low confidence in the vaccination system have disrupted the ability of national programs to meet childhood vaccination targets since 2025. In the next three to five years, helpful evidence and more effective and efficient ways to uncover safety concerns will create market demand. The rapid introduction of clinically effective, safe, and marketable combination products could meet market demand, but concerns related to trust and poor regulatory coordination create significant barriers.

The infant and child multiple vaccine market is projected to grow because of ongoing work to improve vaccination combination formulations, simplify vaccination schedules, and strengthen prevention efforts by governments. Population growth, the need for catch-up immunization, and the expansion of infrastructure will support growth. However, price, supply, regulatory concerns, confidence, complexity of combination vaccines, and confidence will slow progress. In the next three to five years, the companies best placed to gain market share will offer flexibility combined with competitive pricing, strong safety evidence, and reliable capacity; sustainable growth will require cooperation among stakeholders including manufacturers, regulatory bodies, and governments.

List of Infant and Child Multiple Vaccine Market Companies

Companies in the market compete on the basis of product quality offered. Major players in this market focus on expanding their manufacturing facilities, R&D investments, infrastructural development, and leverage integration opportunities across the value chain. Through these strategies infant and child multiple vaccine market companies cater increasing demand, ensure competitive effectiveness, develop innovative products & technologies, reduce production costs, and expand their customer base. Some of the infant and child multiple vaccine market companies profiled in this report include-

• Sanofi
• GSK
• Mitsubishi Tanabe Pharma
• KM Biologics
• Wuhan Institute of Biological Products

Infant and Child Multiple Vaccine Market by Segment

The study includes a forecast for the global infant and child multiple vaccine market by type, application, and region.

Infant and Child Multiple Vaccine Market by Type [Value ($B) from 2019 to 2035]:

• Pentavalent Vaccine
• Quadruple Vaccine
• Triple Vaccine
• Others

Infant and Child Multiple Vaccine Market by Application [Value ($B) from 2019 to 2035]:

• 12 Months Below
• 12 Months Above

Infant and Child Multiple Vaccine Market by Region [Value ($B) from 2019 to 2035]:

• North America
• Europe
• Asia Pacific
• The Rest of the World

Country Wise Outlook for the Infant and Child Multiple Vaccine Market

Global procurement reform, domestic manufacturing, and regulatory growth will shape the combination-vaccine market through 2027. The 2026-2030 Gavi strategy emphasizes routine immunization and sustainable supply, while manufacturers announce an increase in capacity for hexavalent and other pediatric products. According to Lucintel's latest market assessment, these changes will shape market positioning.

• United States: United States Federal procurement continues to be oriented toward routine pediatric coverage, while combination-vaccine manufacturers expand their product offerings. In June 2025, the CDC's Vaccines for Children (VFC) program issued orders to supply approximately 50% of U.S. children, providing continued demand for the public-sector procurement of Vaxelis and Pentacel. This procurement channel will define the market as suppliers will be rewarded for engagement and large, reliable supply under federal contracts.
• China: Chinese manufacturers continue to produce vaccines aligned with both the national and international immunization programs. In March 2025, the WHO reported 75% global coverage of the third dose of Diphtheria, Tetanus, and Pertussis (DTP) which reflects the importance of Chinese manufacturers in global supply chains. Further, regulatory harmonization and investment in production will strengthen China's position for the supply of affordable pediatric combination vaccines.
• Germany: Germany's vaccine manufacturing base is being strengthened by European procurement and industrial partnerships. In January 2025, BioNTech revealed more than €1 billion in cash and cash equivalents to support research and manufacturing and, although its primary focus is oncology, this may be critical to strengthen Europe's pediatric vaccine manufacturing potential in the future.
• India: India is promoting domestic vaccine production through the procurement of public vaccines. In April 2025, the Universal Immunization Program of India expanded routine immunization to cover twelve vaccine preventable diseases, including several combination vaccines. This program has created a path for India's vaccine manufacturers to produce vaccines for the domestic markets and for export.
• Japan: Japan is using a similar strategy to India, but is targeting pediatric vaccines through routine immunization and domestic manufacturing. For April of 2025, the immunization program provided coverage for children from birth through the school age populations and included schedules for multiple combinations of vaccines. The reimbursement from the government and strict product demands have crafted an environment where suppliers focusing on quality, consistency, and supply will fare best.

Features of the Global Infant and Child Multiple Vaccine Market

• Market Size Estimates: infant and child multiple vaccine market size estimation in terms of value ($B).
• Trend and Forecast Analysis: Market trends (2019 to 2026) and forecast (2027 to 2035) by various segments and regions.
• Segmentation Analysis: infant and child multiple vaccine market size by type, application, and region in terms of value ($B).
• Regional Analysis: infant and child multiple vaccine market breakdown by North America, Europe, Asia Pacific, and Rest of the World.
• Growth Opportunities: Analysis of growth opportunities in different type, application, and regions for the infant and child multiple vaccine market.
• Strategic Analysis: This includes M&A, new product development, and competitive landscape of the infant and child multiple vaccine market.

Analysis of competitive intensity of the industry based on Porter's Five Forces model.

If you are looking to expand your business in this or adjacent markets, then contact us. We have done hundreds of strategic consulting projects in market entry, opportunity screening, due diligence, supply chain analysis, M & A, and more.

This report answers following 11 key questions:

• Q.1. What are some of the most promising, high-growth opportunities for the infant and child multiple vaccine market by type (pentavalent vaccine, quadruple vaccine, triple vaccine, and others), application (12 months below and 12 months above), and region (North America, Europe, Asia Pacific, and the Rest of the World)?
• Q.2. Which segments will grow at a faster pace and why?
• Q.3. Which region will grow at a faster pace and why?
• Q.4. What are the key factors affecting market dynamics? What are the key challenges and business risks in this market?
• Q.5. What are the business risks and competitive threats in this market?
• Q.6. What are the emerging trends in this market and the reasons behind them?
• Q.7. What are some of the changing demands of customers in the market?
• Q.8. What are the new developments in the market? Which companies are leading these developments?
• Q.9. Who are the major players in this market? What strategic initiatives are key players pursuing for business growth?
• Q.10. What are some of the competing products in this market and how big of a threat do they pose for loss of market share by material or product substitution?
• Q.11. What M&A activity has occurred in the last 8 years and what has its impact been on the industry?